A 2024 systematic review and meta-analysis that included 53 studies lasting between 12 and 78 weeks and 21,349 patients found that compared with placebo, tirzepatide worked the best for weight loss
[2] Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH
Neuropsychopharmacology 46 , 288296 (2021)
If these early results hold up in replicated trials, that could mean people might not need the treatment indefinitely
Europeans on GLP-1s are actually less likely to change their eating habits than other consumers trying to lose weight, according to Euromonitor
Male participants (44% of the cohort) averaged 22.8%